本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Akari Therapeutics PLC

1.13
-0.0143-1.25%
盤後1.130.00000.00%16:15 EDT
成交量:1.69萬
成交額:1.92萬
市值:3,638.18萬
市盈率:-0.68
高:1.15
開:1.14
低:1.11
收:1.15
資料載入中...
2024/03/29

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/07

SEC問詢函

CORRESP [Cover] - Correspondence
2022/11/04

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2022/10/12

招股説明書

F-1 - Registration statement for certain foreign private issuers
2022/05/16

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals